After the US Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee largely voted against Biogen, Inc.’s Alzheimer’s disease treatment Aduhelm (aducanumab) in November 2020, the Alzheimer’s Association took action, apparently to combat the negative sentiment.
The group scheduled a listening session with Patrizia Cavazzoni, then the acting director of the FDA’s Center for Drug Evaluation...